The strategic partnership expands access to precision medicine, molecular imaging, and radiopharmaceutical therapy.
January 8, 2026
2025 was more than a year of milestones; it was a year of impact. A year of bold advances, compassionate care, and lives touched.
November 28, 2025
BAMF Health dosed the first patient enrolled in a Phase 1 prostate cancer therapy clinical trial sponsored by ARTBIO.
November 25, 2025
With a zest and appreciation for life, at 77 years old, Barbara considered herself the picture of perfect health. But that changed in June of 2025 when she was diagnosed with metastatic HR-/HER2+ breast cancer.
October 2, 2025
Partnership brings new cancer trial and treatments to patients in New York City and Westchester.
September 9, 2025
We’re among the first centers in the country to treat patients in the new “pre-chemo” setting. Here’s what we’re learning—and what we’re still working to understand.
September 2, 2025
Join us this September as we raise awareness for prostate cancer by walking 108 miles!
August 18, 2025
Enrollment for this year’s FutureSolve program is nearly double last year’s.
July 6, 2025
RadioNexus is the world’s first radiopharmaceutical-focused clinical trials network.
June 18, 2025
Prostate cancer patients whose cancer has spread have a game-changing new option for treatment.
May 12, 2025
BAMF Health dosed the first patient in the U.S. for Radiopharm Theranostics’ Phase 2b imaging study of 18F-RAD101 in suspected recurrent brain metastasis.
April 28, 2025
This non-invasive clinical trial aimed to understand the prevalence of a specific biomarker in HR-/HER2+ breast cancer.
April 24, 2025
BAMF Health Chief Medical Advisor Dr. Harshad Kulkarni shares his expert perspectives on the field of Theranostics and where it’s headed.
March 28, 2025
Mike credits the radiopharmaceutical therapy he received at BAMF for shrinking his neuroendocrine tumor and saving his life.
March 27, 2025